American Journal of Cardiovascular Drugs

, Volume 11, Issue 6, pp 355–356


A New Hope for Stroke Prevention in Atrial Fibrillation?


  1. 1.
    Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604–18.PubMedCrossRefGoogle Scholar
  2. 2.
    Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 1501–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003; 108: 711–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 2011; 13: 626–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Kumana CR, Cheung BM, Cheung GT, et al. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. Br J Clin Pharmacol 2005; 60: 347–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Testa L, Biondi-Zoccai GG, Dello Russo A, et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J 2005; 26: 2000–6.PubMedCrossRefGoogle Scholar
  10. 10.
    de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005; 165: 258–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Corley SD, Epstein AE, DiMarco JP, et al., AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109: 1509–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009; 84: 234–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Pamukcu B, Lip GY. Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. Expert Opin Pharmacother 2011; 12: 131–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Singh BN, Connolly SJ, Crijns HJ, et al., EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987–99.PubMedCrossRefGoogle Scholar
  15. 15.
    Køber L, Torp-Pedersen C, McMurray JJ, et al., Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678–87.PubMedCrossRefGoogle Scholar
  16. 16.
    Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597–605.PubMedCrossRefGoogle Scholar
  17. 17.
    Hohnloser SH, Crijns HJ, van Eickels M, et al., ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668–78.PubMedCrossRefGoogle Scholar
  18. 18.
    Connolly SJ, Crijns HJ, Torp-Pedersen C, et al., ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009; 120: 1174–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Dagres N, Varounis C, Iliodromitis EK, et al. Impact of dronedarone on the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials. Am J Cardiovasc Drugs 11 (5): ((to come)).Google Scholar
  20. 20.
    Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score= 1. Thromb Haemost 2010; 103(4): 833–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Mazzaglia G, Filippi A, Alacqua M, et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010; 103(5): 968–75.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.University of Birmingham Centre for Cardiovascular Sciences, City HospitalBirminghamUK

Personalised recommendations